BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12079301)

  • 1. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?
    Saygili U; Guclu S; Uslu T; Erten O; Demir N; Onvural A
    Gynecol Oncol; 2002 Jul; 86(1):57-61. PubMed ID: 12079301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study.
    Vorgias G; Iavazzo C; Savvopoulos P; Myriokefalitaki E; Katsoulis M; Kalinoglou N; Akrivos T
    Gynecol Oncol; 2009 Jan; 112(1):11-5. PubMed ID: 19119502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
    Obeidat B; Latimer J; Crawford R
    Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
    Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
    Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer.
    Brockbank EC; Ind TE; Barton DP; Shepherd JH; Gore ME; A'Hern R; Bridges JE
    Int J Gynecol Cancer; 2004; 14(1):42-50. PubMed ID: 14764028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
    Cooper BC; Sood AK; Davis CS; Ritchie JM; Sorosky JI; Anderson B; Buller RE
    Obstet Gynecol; 2002 Jul; 100(1):59-64. PubMed ID: 12100804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of preoperative serum cancer antigen 125 in malignant ovarian germ cell tumors.
    Kim JH; Park JY; Kim JH; Kim YM; Kim YT; Nam JH
    Taiwan J Obstet Gynecol; 2018 Apr; 57(2):236-240. PubMed ID: 29673667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Segal S; Kopmar A
    Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022).
    Jung DC; Kang S; Kim SC; Kim JW; Nam JH; Ryu SY; Seong SJ; Kim BG
    Gynecol Oncol; 2013 Nov; 131(2):336-40. PubMed ID: 23954903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.
    Dowdy SC; Mullany SA; Brandt KR; Huppert BJ; Cliby WA
    Cancer; 2004 Jul; 101(2):346-52. PubMed ID: 15241833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Lurian M; Gdalevich M; Kapustian V; Piura E; Schneider D; Lavie O; Levy T; Fishman A; Dgani R; Levavi H; Beller U
    Eur J Surg Oncol; 2005 Nov; 31(9):1006-10. PubMed ID: 16005601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
    Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
    Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative predictors for residual tumor after surgery in patients with ovarian carcinoma.
    de Jong D; Eijkemans MJ; Lie Fong S; Gerestein CG; Kooi GS; Baalbergen A; van der Burg ME; Burger CW; Ansink AC
    Oncology; 2007; 72(5-6):293-301. PubMed ID: 18198490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A proteomics panel for predicting optimal primary cytoreduction in stage III/IV ovarian cancer.
    Risum S; Høgdall E; Engelholm SA; Fung E; Lomas L; Yip C; Petri AL; Nedergaard L; Lundvall L; Høgdall C
    Int J Gynecol Cancer; 2009 Dec; 19(9):1535-8. PubMed ID: 19955932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.